HOME >> BIOLOGY >> NEWS
When combining new oral anti-cancer agents with standard chemotherapy, timing may be crucial

(NEW ORLEANS) -- Timing may be everything when it comes to combining the new-generation oral, molecularly targeted anti-cancer agents with standard chemotherapy drugs, UC Davis Cancer Center researchers reported Saturday at the annual meeting of the American Society of Clinical Oncologists.

"Many of the new molecularly targeted anti-cancer agents work by inhibiting cancer cell division and growth -- but in doing so, the new agents could diminish the effectiveness of chemotherapy, which depends on rapid cell cycling," said senior investigator Paul Gumerlock, professor of hematology/oncology at UC Davis Cancer Center. "Because of this, it could be very important in what sequence the new agents are combined with standard chemotherapy drugs."

To test the notion, Gumerlock and his colleagues focused on a new oral epidermal growth factor receptor inhibitor known as erlotinib. Recently, several large clinical trials have compared standard chemotherapy alone to standard chemotherapy plus an oral EGFR inhibitor like erlotinib in the treatment of non-small cell lung cancer. Little if any benefit was found from the addition of an EGFR inhibitor in these trials, in which the EGFR inhibitor and chemotherapy were administered simultaneously.

The UC Davis Cancer Center team set out to determine whether sequential administration would make a difference. The researchers tested erlotinib alone, the standard chemotherapy agent docetaxel alone, the two drugs simultaneously, and the two drugs sequentially. All the tests were done in the laboratory using human non-small cell lung cancer cells.

"We predicted that giving docetaxel first, then erlotinib, would be more effective than giving the erlotinib first, giving both drugs simultaneously or giving either drug alone" Gumerlock said. "And that proved to be true."

Docetaxel, a standard first-line chemotherapy drug for non-small cell lung cancer, works in th
'"/>


5-Jun-2004


Page: 1 2 3

Related biology news :

1. Emory researchers map structure of anti-cancer molecule
2. New way to lock DNA-slicing enzyme onto chromosomes could lead to novel anti-cancer drugs
3. Unraveling a protein, researchers uncover mechanics of anti-cancer agent
4. Lycopenes anti-cancer effect linked to other tomato components
5. Hebrew University researcher wins prize for work leading to new anti-cancer drugs
6. Process triggered by some anti-cancer drugs causes tumors in mice, study finds
7. Evolution boosted anti-cancer prowess of a primordial gene
8. Inhibitor of novel cancer target, LPAAT-beta, demonstrates selective anti-cancer effects
9. Researchers elucidate machinery of major anti-cancer target
10. Genetic engineering could salvage once-promising anti-cancer agents
11. Bacteria discovered in cave produce potential anti-cancer drug

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/19/2018)... ROCHELLE, Va. (PRWEB) , ... December 19, 2018 , ... ... former Scientific Reviewer and Compliance Officer at the FDA Center for Devices and Radiological ... with NDA Partners as an Expert Consultant since 2015, and she has more than ...
(Date:12/18/2018)... ... December 18, 2018 , ... The nation’s leader in ... marketing. The technology has been effective at reducing patient acquisition costs by over ... with clients nationwide on patient acquisition marketing programs. Traditional marketing for stem cell ...
(Date:12/14/2018)... (PRWEB) , ... December 14, 2018 , ... ... patent number 9,703,929 entitled “Method and System for Microbiome-Derived Diagnostics and Therapeutics” by ... date of October 21, 2014. The patent is an invention by uBiome collaborators ...
Breaking Biology News(10 mins):
(Date:1/4/2019)... N.C. (PRWEB) , ... January 04, 2019 , ... ... is pleased to welcome Ted Hoffman to the firm. Ted will be joining ... of experience working in and providing consulting services to the pharmaceutical industry. At ...
(Date:12/20/2018)... ... December 20, 2018 , ... New Year’s brings reflection and desire to ... in the European Union (EU) on the horizon, Jim Kasic, president and CEO of ... to the EU Medical Device Regulation (MDR), digital health, and big data are just ...
(Date:12/18/2018)... ... December 18, 2018 , ... USDM Life Sciences, the ... sciences industry, unveiled a completely redesigned website at http://www.usdm.com . The site ... for their valued clients and business partners. , The website has a ...
(Date:12/13/2018)... (PRWEB) , ... December 12, 2018 , ... ... other life science software solutions, announces the Limfinity® ML (Machine Learning) addition for ... trained machine learning models within Limfinity® solutions. In the module, trained models make ...
Breaking Biology Technology:
Cached News: